5 and 10 years of age, who were brought to Germany by a humanitarian organization for surgery on severe gun wounds to their lower extremities (foot and thigh with chronic osteomyelitis, respectively). To our knowledge, these reports are the first of cutaneous diphtheria in gunshot wounds in recent years. Moreover, in the patient with the thigh wound, C. diphtheriae was also isolated from a deep fistula, which suggests involvement of C. diphtheriae in the chronic osteomyelitis.

As in the United Kingdom, all cases of diphtheria reported since 1997 were caused by C. diphtheriae mitis. In 4 of 5 cutaneous diphtheria patients who had an available medical history, mixed infections with Staphylococcus aureus and Streptococcus pyogenes were found; 3 of 5 patients were not sufficiently vaccinated against diphtheria as recommended. Systemic symptoms, such as malaise and general weakness, developed in the 20-year-old Thailand tourist, although she had received a booster dose just before her travel. Cutaneous diphtheria must be expected even in vaccinated patients; for instance, among serum samples of 287 healthy German adults with a complete record of basic immunization against diphtheria, only 42.2% showed full serologic protection as indicated by antitoxin levels ≥ 0.1 IU/mL (3).

As de Benoist et al. outline, cutaneous diphtheria might be difficult to diagnose because of its unspecific clinical appearance and the presence of mixed infections in chronic nonhealing skin lesions. Because of the nearly complete disappearance of cutaneous diphtheria in many parts of the western world, microbiologists lack experience in identifying C. diphtheriae grown from specimens. From 1997 to 2003, approximately one fifth of the strains sent to our Consiliary Laboratory on Diphtheria for species identification and toxin testing were either nondiphtheria Corynebacterium spp. or noncoryneform bacteria of different genera (including lactobacilli, Dermabacter hominis, and Propionibacterium acnes).

Clinicians (4) and microbiologists (5) should be aware of the possibility of cutaneous diphtheria in chronically infected skin lesions in patients returning from disease-endemic regions. Medical personnel should include this in civilian as well as military health services, since our cases indicate that toxigenic C. diphtheriae might affect not only travel-related skin injuries caused by leisure or tourist activities but also wounds in patients from war regions in diphtheria-endemic areas.

Andreas Sing* and Jürgen Heesemann*
*Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Munich, Germany

References


Address for correspondence: Andreas Sing, Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, National Consiliary Laboratory on Diphtheria, Pettenkoferstrasse 9a, 80336 Munich, Germany; fax: 49-89-5160-5223; email: sing@m3401.mpk.med.uni-muenchen.de

Antimicrobial Drug Consumption in Companion Animals

To the Editor: During the last decade, use of antimicrobial drugs for growth promotion and therapeutic treatment in food animals has received much attention. The reservoir of resistant bacteria in food animals implies a potential risk for transfer of resistant bacteria, or resistance genes, from food animals to humans. Subsequent emergence of infections in humans, caused by resistant bacteria originating from the animal reservoir, is of great concern. These unintended consequences of antimicrobial drug use in animals led to termination of antimicrobial growth promoters in food animals in countries in the European Union, including Denmark, where the consumption of antimicrobial drugs by production animals was reduced by 50% from 1994 to 2003 (1).

In Denmark, the VetStat program monitors all veterinary use of medicines for animals. VetStat is based on reporting from the pharmacies and from veterinary practitioners and contains detailed information, such as animal species, reason for prescription, and dosage on each prescription. In Denmark, antimicrobial drugs can be obtained only by prescription and only at pharmacies.

So far, use of antimicrobial drugs in companion animals has received little attention; monitoring programs have focused on antimicrobial drug consumption in food animals. According to data generated by the VetStat program in 2003, consumption of fluoroquinolones and cephalosporins in companion animals was substantial when compared to consumption in food animals (1). Fluoroquinolones and cephalosporins are antimicrobial drugs ranked by the U.S. Food and Drug Administration as critically important in human medicine, and for which emergence of...
resistant bacteria is especially undesirable (2). Considering the shared environment of humans and companion animals, transfer of resistant bacteria or mobile resistance determinants from companion animals to humans would be possible, and emergence of resistance to fluoroquinolones and cephalosporins in companion animals should be a matter of concern.

Several scientific publications have reported the occurrence of the same resistance genes in companion animals and in humans (3–6) and the possible transfer of bacteria between companion animals and humans (3–9). Companion animal owners and their families are likely in close contact with their animals daily, which provides the opportunity for transfer of bacteria between companion animals and humans. A large proportion of the human population presumably has daily contact with companion animals, not only in Denmark but also in other countries. In Denmark, 20% of families own dogs and 16% own cats (10).

In 2002, legal restrictions aimed to reduce the usage of fluoroquinolones in food animals were imposed in Denmark. The total annual consumption of fluoroquinolones in animals (companion and food animals) in Denmark was reduced from 183 kg in 2001 to 53 kg in 2003 (1). Of these 53 kg of fluoroquinolones, almost half (24 kg) was used in companion animals (data based on reporting on use in veterinary practice and sales from pharmacies on prescription). These data document that fluoroquinolones remain widely used for infections in companion animals, even though the emergence of fluoroquinolone resistance in bacteria is especially undesirable and regarded as a human health hazard. A similar situation exists with cephalosporins. The total consumption of cephalosporins in animals (companion and food animals) in Denmark in 2003 was 461 kg, of which more than half (254 kg) was consumed by companion animals (1).

Thus, a comparatively small number of companion animals (550,000 dogs and 650,000 cats) (10) consume approximately the same amount of fluoroquinolones and cephalosporins as consumed annually in the much larger population of food animals in Denmark (23 million slaughter pigs, 130 million broiler chickens, and 1.2 million cattle and dairy cows) (10). We do not believe that antimicrobial drugs are more generously prescribed for companion animals in Denmark than in other industrialized countries.

Rather, the data presented here reflect the apparent contrast between policies of antimicrobial drug use for food animals and policies for companion animals. The use of these antimicrobial drugs is avoided or restricted in food animals to minimize spread of resistance, while in companion animals prescription continues unimpeded. This situation may create undesirable antimicrobial drug resistance in bacteria, which may subsequently spread to humans from the previously neglected reservoir in companion animals.

This work is a part of The Danish Integrated Antimicrobial Resistance Monitoring and Research Programme (DANMAP), and was funded by the Danish Ministry of Food, Agriculture and Fisheries and the Danish Ministry of the Interior and Health.

Ole E. Heuer,* Vibeke Frøkjær Jensen,* and Anette M. Hammerum†
*Danish Institute for Food and Veterinary Research, Søborg, Denmark; and †National Centre for Antimicrobials and Infection Control, Copenhagen, Denmark

References

Address for correspondence: Ole E. Heuer, Department of Epidemiology and Risk Assessment, Danish Institute for Food and Veterinary Research, Morkøh Bygade 19, DK-2860 Søborg, Denmark; fax: 45-7234-7028; email: oeh@dfvf.dk

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is appreciated.